Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 14/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | STS | P08842 | 1/20 | 0.51 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412710 | 0.94 | HTR1A (0.50) | HTR1ASLC6A4ALDH1A1EPHX2STS | |
| SCHEMBL20971864 | 0.85 | EPHX2 (0.56) | ALDH1A1EPHX2STSTGFBR1 | |
| SCHEMBL5214882 | 0.84 | EPHX2 (0.57) | ALDH1A1EPHX2STSTGFBR1 | |
| SCHEMBL3582211 | 0.84 | EPHX2 (0.55) | ALDH1A1EPHX2STSTGFBR1 | |
| SCHEMBL6416990 | 0.83 | IDO1 (0.43) | HTR1ASLC6A4ALDH1A1TGFBR1 | |
| SCHEMBL6416993 | 0.83 | GPR119 (0.48) | HTR1ASLC6A4ALDH1A1TGFBR1 | |
| SCHEMBL6409804 | 0.82 | SLC6A4 (0.61) | HTR1ASLC6A4 | |
| SCHEMBL8602574 | 0.82 | TGFBR1 (0.54) | ALDH1A1EPHX2STSTGFBR1 | |
| SCHEMBL28169019 | 0.81 | ALDH1A1 (0.62) | ALDH1A1STSTGFBR1 | |
| SCHEMBL6411034 | 0.81 | HTR1A (0.62) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1304324-B1 | SEROTONIN REUPTAKE INHIBITORS | DAINIPPON SUMITOMO PHARMA CO (JP) | 2007-10-03 | — | — | EP | disclosed |
| US-20050065140-A1 | Serotonine reuptake inhibitor | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1466901-A1 | SEROTONINE REUPTAKE INHIBITOR | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-10-13 | — | — | EP | disclosed |
| US-6787560-B2 | PSYCHOLOGICAL DISORDERS; ANTIDEPRESSANTS | SUMITOMO PHARMACEUTICALS COMPANY LIMITED (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030191126-A1 | Psychological disorders; antidepressants | SUMITOMO PHARMACEUTICALS COMPANY LIMITED | 2003-10-09 | — | — | US | disclosed |
| EP-1304324-A1 | SEROTONIN REUPTAKE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191126-A1 | Psychological disorders; antidepressants | CRH, HTR2C, HTR1A | HTR1A 3/4885SLC6A4 10/4885ALDH1A1 2672/4885 |
| US-20050065140-A1 | Serotonine reuptake inhibitor | HTR1A, SLC6A4, SLC6A2 | HTR1A 1/4885SLC6A4 2/4885ALDH1A1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.